Imugene Limited
Sydney
33 articles with Imugene Limited
-
Imugene’s onCARlytics combination with Celularity’s placental-derived off-the-shelf allogeneic CYCART-19 T cells preclinical data presented at SITC Annual Meeting
11/10/2022
Imugene Limited (ASX:IMU) are pleased to announce that data from preclinical studies of Imugene’s onCARlytics (CF33-CD19) oncolytic virus in combination with Celularity’s placental-derived off-the-shelf allogeneic CYCART-19 T cells was presented at the renowned Annual Meeting of the Society for Immunotherapy of Cancer (SITC).
-
A roundup of last week's top clinical trial announcements and news, including updates from Pfizer, BioNTech, Ocugen and more.
-
Imugene and City of Hope announced that the first patient has begun treatment in a Phase I clinical trial, investigating the safety and efficacy of CF33-hNIS in adults with metastatic or advanced tumors.
-
Imugene announced a clinical trial collaboration and supply deal with Merck, while Merck said it is halting a Keytruda combination trial with AstraZeneca in prostate cancer.
-
Imugene Announces Clinical Trial Collaboration with Merck & Co., Inc., Kenilworth, NJ., USA to Evaluate HER-Vaxx in Combination with Pembrolizumab for Treatment of Gastric Cancer
3/14/2022
Imugene (ASX: IMU) today announced a new clinical trial collaboration and supply agreement with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ, USA, to evaluate the safety and efficacy of Imugene’s HER-Vaxx, a B-cell activating immunotherapy, in combination with MSD’s anti-PD-1 therapy, pembrolizumab (KEYTRUDA®), in patients with HER-2 positive gastric cancer.
-
Imugene Announces Clinical Trial Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer to Evaluate HER-Vaxx in Combination with Avelumab for Treatment of Gastric Cancer
11/17/2021
Imugene announced a new clinical trial supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer Inc. to evaluate the safety and efficacy of Imugene’s HER-Vaxx, a B-cell activating immunotherapy, in combination with avelumab, an immune checkpoint inhibitor targeting PD-L1, in patients with HER-2 positive gastric cancer.
-
Imugene and Eureka Therapeutics Announce Strategic Collaboration to Accelerate Advancement of Oncolytic Virus and T-Cell Therapy in Solid Tumours
11/1/2021
Imugene Ltd and Eureka Therapeutics, Inc. today announced a strategic collaboration to evaluate Imugene’s CD19 oncolytic virus onCARlytics technology in combination with Eureka’s anti-CD19 ARTEMIS® T-cell therapy for the treatment of solid tumours.
-
A Phase II study shows the vaccine by Imugene Limited improved survival rates and overall response in patients with HER2-positive stomach or gastroesophageal junction cancer.
-
Imugene Licenses Cd19 Oncolytic Virus From City of Hope to Turn Car T Therapy Against Solid Tumors
5/18/2021
Imugene enhances portfolio with novel CD19-expressing oncolytic virus from City of Hope, a comprehensive cancer center in Los Angeles, California, to be developed in combination with CD19-CAR T cell therapy
-
City of Hope Researchers Receive Large US Department of Defense Grant to Study Imugene Oncolytic Virotherapy CF33 in Gastric Cancer
10/23/2019
Imugene Limited announced that prominent City of Hope researchers Yanghee Woo, MD, Associate Clinical Professor, Department of Surgery and Director, Gastroenterology Minimally Invasive Therapy Program, together with Yuman Fong, MD, Professor and Chair of the Department of Surgery, received a AU$564,173 US Department of Defense Grant
-
European Society of Medical Oncology Congress Presentations Show B-Cell Vaccine Combinations Inhibit Cancer Growth in Preclinical Models
10/1/2019
Imugene Limited announced two presentations by medical investigators at the European Society of Medical Oncology in Barcelona Spain showed combining its HER2 vaccines with PD1 vaccines reduced cancer growth in a number of standard preclinical models.
-
Comprehensive Phase 1b HER-Vaxx Cancer Vaccine Results Presented at the European Society of Medical Oncology (ESMO) Congress
10/1/2019
Imugene Limited, a clinical stage immuno-oncology company, announced comprehensive clinical data results from the Phase Ib clinical study of its HER-Vaxx anti-cancer vaccine were presented at the European Society of Medical Oncology in Barcelona, Spain held from 27 September to 1 October 2019.
-
Imugene Enhances Portfolio with Compelling Oncolytic Virus from City of Hope, a Cancer Centre in Los Angeles, California
7/15/2019
Phase 1 clinical trial anticipated to commence in 2020
-
New HER-Vaxx Cancer Vaccine trial data presented at the European Society of Medical Oncology World Congress on Gastrointestinal Cancer
7/8/2019
Imugene Limited, a clinical stage immuno-oncology company, announced new clinical data from the Phase Ib study of its HER-Vaxx cancer vaccine showing cancer fighting antibody and clinical response rates continue to be positive in the patients receiving the optimal biological dose of vaccine.
-
IMUGENE: Updated Phase Ib HER-Vaxx data presented at the American Society of Clinical Oncology 2019 Annual Meeting
6/4/2019
Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced positive data from the ongoing patients in the Phase Ib study of its HER-Vaxx cancer vaccine was presented at the prestigious American Society of Clinical Oncology (ASCO) annual meeting in Chicago Illinois, USA 31 May to 3 June 2019.
-
Global Biotechnology and Venture Capital Executive Joins Imugene Board
5/20/2019
Dr. Eckstein recently joined Apollo Ventures as Managing Partner.
-
Positive New Data on Imugene’s HER-Vaxx Cancer Vaccine Phase Ib trial presented at the American Association for Cancer Research 2019 Annual Meeting
4/2/2019
Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today presented new data on the Phase 1b study of its HER-Vaxx cancer vaccine at the American Association for Cancer Research (AACR) 2019 Annual Meeting in Atlanta, Georgia, USA.
-
New Data on Imugene’s Lead PD-1 KEY-Vaxx and HER-2 B-Vaxx Cancer Vaccines presented at the American Association for Cancer Research 2019 Annual Meeting
4/2/2019
Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced Dr Tanios Bekaii-Saab from the Mayo Clinic presented new data on the KEY-Vaxx and B-Vaxx cancer vaccine programs at the American Association for Cancer Research (AACR) 2019 Annual Meeting.
-
Imugene’s Pre-IND FDA Meeting Provides Guidance for KEY-Vaxx Immunotherapy Clinical Development Plan
3/20/2019
The meeting was productive and provided Imugene with a clear roadmap for a successful IND submission and subsequent clinical development of KEY-Vaxx.
-
Imugene Announces First Patient Dosed in the Open-Label Phase 2 Study with HER-Vaxx Cancer Vaccine for Advanced Gastric Cancer
3/14/2019
Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced dosing of the first patient in an open-label, randomised multi-centre Phase 2 study with its HER-Vaxx (IMU-131) cancer vaccine for the treatment of HER-2 positive gastric cancer patients.